Emcure Pharma launches weight loss drug Poviztra in India
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The new facility is expected to generate 500-600 new jobs in the region
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
Subscribe To Our Newsletter & Stay Updated